시장보고서
상품코드
1090252

세계의 흉막염 치료 시장(2022-2026년)

Global Pleurodynia Treatment Market 2022-2026

발행일: | 리서치사: TechNavio (Infiniti Research Ltd.) | 페이지 정보: 영문 120 Pages | 배송안내 : 즉시배송

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 흉막염 치료 시장 규모는 2022-2026년 2,461만 달러의 증가가 전망되며, 예측 기간 중 CAGR로 4.76%의 성장이 예측됩니다.

시장은 바이러스 감염증의 증가, 조사, 헬스케어 분야용 연구개발의 증가, 의약품의 적정 사용과 유통을 위한 구상에 의해 촉진되고 있습니다.

세계의 흉막염 치료 시장에 대해 조사분석했으며, 시장 규모·예측, 동향, 성장 촉진요인·과제, 약 25사의 벤더를 다룬 벤더 분석 등을 정리하여 전해드립니다.

목차

제1장 개요

  • 시장 개요

제2장 시장 구도

  • 시장 에코시스템

제3장 시장 규모

  • 시장의 정의
  • 시장 부문 분석
  • 시장 규모 : 2021년
  • 시장 전망 : 2021-2026년의 예측

제4장 Five Forces 분석

  • Five Forces 요약
  • 구매자의 교섭력
  • 공급업체의 교섭력
  • 신규 기업의 위협
  • 대체품의 위협
  • 경쟁사의 위협
  • 시장 현황

제5장 시장 세분화 : 요법별

  • 시장 부문
  • 비교 : 요법별
  • 진통제 - 시장 규모와 예측 : 2021-2026년
  • 면역글로불린 - 시장 규모와 예측 : 2021-2026년
  • 시장 기회 : 요법별

제6장 고객 상황

  • 고객 상황의 개요

제7장 지역별 상황

  • 지역별 세분화
  • 지역별 비교
  • 북미 - 시장 규모와 예측 : 2021-2026년
  • 유럽 - 시장 규모와 예측 : 2021-2026년
  • 아시아 - 시장 규모와 예측 : 2021-2026년
  • 기타 지역(ROW) - 시장 규모와 예측 : 2021-2026년
  • 미국 - 시장 규모와 예측 : 2021-2026년
  • 캐나다 - 시장 규모와 예측 : 2021-2026년
  • 덴마크 - 시장 규모와 예측 : 2021-2026년
  • 중국 - 시장 규모와 예측 : 2021-2026년
  • 노르웨이 - 시장 규모와 예측 : 2021-2026년
  • 시장 기회 : 지역 상황별

제8장 촉진요인, 과제 및 동향

  • 시장 촉진요인
  • 시장이 해결해야 할 과제
  • 촉진요인과 과제의 영향
  • 시장 동향

제9장 벤더 구도

  • 개요
  • 벤더 구도
  • 혼란의 상황
  • 업계의 리스크

제10장 벤더 분석

  • 대상 벤더
  • 벤더의 시장 포지셔닝
  • Abbott Laboratories
  • GlaxoSmithKline Plc
  • Hudson Pharma
  • Johnson and Johnson
  • Merck and Co. Inc.
  • Novartis AG
  • Opsonin Pharma Ltd.
  • Pfizer Inc.
  • Reckitt Benckiser Group PLC
  • Sanofi

제11장 부록

KSA 22.06.27

Technavio has been monitoring the pleurodynia treatment market and it is poised to grow by $ 24.61 million during 2022-2026, accelerating at a CAGR of 4.76% during the forecast period. Our report on the pleurodynia treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the growing prevalence of viral infections, increasing research and development in healthcare, and initiatives for the proper use and distribution of drugs.

The pleurodynia treatment market analysis includes the therapy segment and geographic landscape.

Technavio's pleurodynia treatment market is segmented as below:

By Therapy

  • Painkillers
  • Immunoglobulin

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)

This study identifies the growing partnerships as one of the prime reasons driving the pleurodynia treatment market growth during the next few years. Also, the increasing number of mergers and acquisitions and technological advancements will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on pleurodynia treatment market covers the following areas:

  • Pleurodynia treatment market sizing
  • Pleurodynia treatment market forecast
  • Pleurodynia treatment market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading pleurodynia treatment market vendors that include Abbott Laboratories, GlaxoSmithKline Plc, Hudson Pharma, Johnson and Johnson, Merck and Co. Inc., Novartis AG, Opsonin Pharma Ltd., Pfizer Inc., Reckitt Benckiser Group PLC, and Sanofi. Also, the pleurodynia treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary

  • 1.1 Market overview
  • Exhibit 01: Executive Summary - Chart on Market Overview
  • Exhibit 02: Executive Summary - Data Table on Market Overview
  • Exhibit 03: Executive Summary - Chart on Global Market Characteristics
  • Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
  • Exhibit 05: Executive Summary - Chart on Market Segmentation by Therapy
  • Exhibit 06: Executive Summary - Chart on Incremental Growth
  • Exhibit 07: Executive Summary - Data Table on Incremental Growth
  • Exhibit 08: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
  • Exhibit 09: Parent market
  • Exhibit 10: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
  • Exhibit 11: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
  • Exhibit 12: Market segments
  • 3.3 Market size 2021
  • 3.4 Market outlook: Forecast for 2021-2026
  • Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
  • Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
  • Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
  • Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

  • 4.1 Five forces summary
  • Exhibit 17: Five forces analysis - Comparison between 2021 and 2026
  • 4.2 Bargaining power of buyers
  • Exhibit 18: Chart on Bargaining power of buyers - Impact of key factors 2021 and 2026
  • 4.3 Bargaining power of suppliers
  • Exhibit 19: Bargaining power of suppliers - Impact of key factors in 2021 and 2026
  • 4.4 Threat of new entrants
  • Exhibit 20: Threat of new entrants - Impact of key factors in 2021 and 2026
  • 4.5 Threat of substitutes
  • Exhibit 21: Threat of substitutes - Impact of key factors in 2021 and 2026
  • 4.6 Threat of rivalry
  • Exhibit 22: Threat of rivalry - Impact of key factors in 2021 and 2026
  • 4.7 Market condition
  • Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

5 Market Segmentation by Therapy

  • 5.1 Market segments
  • Exhibit 24: Chart on Therapy - Market share 2021-2026 (%)
  • Exhibit 25: Data Table on Therapy - Market share 2021-2026 (%)
  • 5.2 Comparison by Therapy
  • Exhibit 26: Chart on Comparison by Therapy
  • Exhibit 27: Data Table on Comparison by Therapy
  • 5.3 Painkillers - Market size and forecast 2021-2026
  • Exhibit 28: Chart on Painkillers - Market size and forecast 2021-2026 ($ million)
  • Exhibit 29: Data Table on Painkillers - Market size and forecast 2021-2026 ($ million)
  • Exhibit 30: Chart on Painkillers - Year-over-year growth 2021-2026 (%)
  • Exhibit 31: Data Table on Painkillers - Year-over-year growth 2021-2026 (%)
  • 5.4 Immunoglobulin - Market size and forecast 2021-2026
  • Exhibit 32: Chart on Immunoglobulin - Market size and forecast 2021-2026 ($ million)
  • Exhibit 33: Data Table on Immunoglobulin - Market size and forecast 2021-2026 ($ million)
  • Exhibit 34: Chart on Immunoglobulin - Year-over-year growth 2021-2026 (%)
  • Exhibit 35: Data Table on Immunoglobulin - Year-over-year growth 2021-2026 (%)
  • 5.5 Market opportunity by Therapy
  • Exhibit 36: Market opportunity by Therapy ($ million)

6 Customer Landscape

  • 6.1 Customer landscape overview
  • Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

  • 7.1 Geographic segmentation
  • Exhibit 38: Chart on Market share By Geographical Landscape 2021-2026 (%)
  • Exhibit 39: Data Table on Market share By Geographical Landscape 2021-2026 (%)
  • 7.2 Geographic comparison
  • Exhibit 40: Chart on Geographic comparison
  • Exhibit 41: Data Table on Geographic comparison
  • 7.3 North America - Market size and forecast 2021-2026
  • Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million)
  • Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
  • Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%)
  • Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%)
  • 7.4 Europe - Market size and forecast 2021-2026
  • Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million)
  • Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
  • Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%)
  • Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%)
  • 7.5 Asia - Market size and forecast 2021-2026
  • Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million)
  • Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
  • Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%)
  • Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%)
  • 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
  • Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
  • Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
  • Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
  • Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
  • 7.7 US - Market size and forecast 2021-2026
  • Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million)
  • Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million)
  • Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%)
  • Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%)
  • 7.8 Canada - Market size and forecast 2021-2026
  • Exhibit 62: Chart on Canada - Market size and forecast 2021-2026 ($ million)
  • Exhibit 63: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
  • Exhibit 64: Chart on Canada - Year-over-year growth 2021-2026 (%)
  • Exhibit 65: Data Table on Canada - Year-over-year growth 2021-2026 (%)
  • 7.9 Denmark - Market size and forecast 2021-2026
  • Exhibit 66: Chart on Denmark - Market size and forecast 2021-2026 ($ million)
  • Exhibit 67: Data Table on Denmark - Market size and forecast 2021-2026 ($ million)
  • Exhibit 68: Chart on Denmark - Year-over-year growth 2021-2026 (%)
  • Exhibit 69: Data Table on Denmark - Year-over-year growth 2021-2026 (%)
  • 7.10 China - Market size and forecast 2021-2026
  • Exhibit 70: Chart on China - Market size and forecast 2021-2026 ($ million)
  • Exhibit 71: Data Table on China - Market size and forecast 2021-2026 ($ million)
  • Exhibit 72: Chart on China - Year-over-year growth 2021-2026 (%)
  • Exhibit 73: Data Table on China - Year-over-year growth 2021-2026 (%)
  • 7.11 Norway - Market size and forecast 2021-2026
  • Exhibit 74: Chart on Norway - Market size and forecast 2021-2026 ($ million)
  • Exhibit 75: Data Table on Norway - Market size and forecast 2021-2026 ($ million)
  • Exhibit 76: Chart on Norway - Year-over-year growth 2021-2026 (%)
  • Exhibit 77: Data Table on Norway - Year-over-year growth 2021-2026 (%)
  • 7.12 Market opportunity By Geographical Landscape
  • Exhibit 78: Market opportunity By Geographical Landscape ($ million)

8 Drivers, Challenges, and Trends

  • 8.1 Market drivers
  • 8.2 Market challenges
  • 8.3 Impact of drivers and challenges
  • Exhibit 79: Impact of drivers and challenges in 2021 and 2026
  • 8.4 Market trends

9 Vendor Landscape

  • 9.1 Overview
  • 9.2 Vendor landscape
  • Exhibit 80: Overview on Criticality of inputs and Factors of differentiation
  • 9.3 Landscape disruption
  • Exhibit 81: Overview on factors of disruption
  • 9.4 Industry risks
  • Exhibit 82: Impact of key risks on business

10 Vendor Analysis

  • 10.1 Vendors covered
  • Exhibit 83: Vendors covered
  • 10.2 Market positioning of vendors
  • Exhibit 84: Matrix on vendor position and classification
  • 10.3 Abbott Laboratories
  • Exhibit 85: Abbott Laboratories - Overview
  • Exhibit 86: Abbott Laboratories - Business segments
  • Exhibit 87: Abbott Laboratories - Key news
  • Exhibit 88: Abbott Laboratories - Key offerings
  • Exhibit 89: Abbott Laboratories - Segment focus
  • 10.4 GlaxoSmithKline Plc
  • Exhibit 90: GlaxoSmithKline Plc - Overview
  • Exhibit 91: GlaxoSmithKline Plc - Business segments
  • Exhibit 92: GlaxoSmithKline Plc - Key news
  • Exhibit 93: GlaxoSmithKline Plc - Key offerings
  • Exhibit 94: GlaxoSmithKline Plc - Segment focus
  • 10.5 Hudson Pharma
  • Exhibit 95: Hudson Pharma - Overview
  • Exhibit 96: Hudson Pharma - Product / Service
  • Exhibit 97: Hudson Pharma - Key offerings
  • 10.6 Johnson and Johnson
  • Exhibit 98: Johnson and Johnson - Overview
  • Exhibit 99: Johnson and Johnson - Business segments
  • Exhibit 100: Johnson and Johnson - Key news
  • Exhibit 101: Johnson and Johnson - Key offerings
  • Exhibit 102: Johnson and Johnson - Segment focus
  • 10.7 Merck and Co. Inc.
  • Exhibit 103: Merck and Co. Inc. - Overview
  • Exhibit 104: Merck and Co. Inc. - Business segments
  • Exhibit 105: Merck and Co. Inc. - Key news
  • Exhibit 106: Merck and Co. Inc. - Key offerings
  • Exhibit 107: Merck and Co. Inc. - Segment focus
  • 10.8 Novartis AG
  • Exhibit 108: Novartis AG - Overview
  • Exhibit 109: Novartis AG - Business segments
  • Exhibit 110: Novartis AG - Key offerings
  • Exhibit 111: Novartis AG - Segment focus
  • 10.9 Opsonin Pharma Ltd.
  • Exhibit 112: Opsonin Pharma Ltd. - Overview
  • Exhibit 113: Opsonin Pharma Ltd. - Product / Service
  • Exhibit 114: Opsonin Pharma Ltd. - Key offerings
  • 10.10 Pfizer Inc.
  • Exhibit 115: Pfizer Inc. - Overview
  • Exhibit 116: Pfizer Inc. - Product / Service
  • Exhibit 117: Pfizer Inc. - Key news
  • Exhibit 118: Pfizer Inc. - Key offerings
  • 10.11 Reckitt Benckiser Group PLC
  • Exhibit 119: Reckitt Benckiser Group PLC - Overview
  • Exhibit 120: Reckitt Benckiser Group PLC - Business segments
  • Exhibit 121: Reckitt Benckiser Group PLC - Key offerings
  • Exhibit 122: Reckitt Benckiser Group PLC - Segment focus
  • 10.12 Sanofi
  • Exhibit 123: Sanofi - Overview
  • Exhibit 124: Sanofi - Business segments
  • Exhibit 125: Sanofi - Key news
  • Exhibit 126: Sanofi - Key offerings
  • Exhibit 127: Sanofi - Segment focus

11 Appendix

  • 11.1 Scope of the report
  • 11.2 Inclusions and exclusions checklist
  • Exhibit 128: Inclusions checklist
  • Exhibit 129: Exclusions checklist
  • 11.3 Currency conversion rates for US$
  • Exhibit 130: Currency conversion rates for US$
  • 11.4 Research methodology
  • Exhibit 131: Research methodology
  • Exhibit 132: Validation techniques employed for market sizing
  • Exhibit 133: Information sources
  • 11.5 List of abbreviations
  • Exhibit 134: List of abbreviations
    • health: Includes veterinary drugs (excluded from the scope of the report)
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제